Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

NCT03541603 is registered in ClinicalTrials.gov with Tenax Therapeutics, Inc. as lead sponsor.

NCT NCT03541603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03541603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Lead sponsor
Tenax Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 14, 2018
Completion date
April 7, 2020
Enrollment
44 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with normal ejection fraction, heart failure, right sided, hypertension pulmonary secondary